14,672 Shares in Inogen Inc (NASDAQ:INGN) Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new stake in shares of Inogen Inc (NASDAQ:INGN) in the third quarter, according to the company in its most recent filing with the SEC. The fund purchased 14,672 shares of the medical technology company’s stock, valued at approximately $1,395,000. GSA Capital Partners LLP owned about 0.07% of Inogen as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in INGN. Schroder Investment Management Group bought a new stake in shares of Inogen in the 2nd quarter worth approximately $132,000. Ameritas Investment Partners Inc. raised its holdings in shares of Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 86 shares during the period. Sei Investments Co. raised its holdings in shares of Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after purchasing an additional 443 shares during the period. Victory Capital Management Inc. raised its holdings in Inogen by 17.8% during the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after acquiring an additional 307 shares during the period. Finally, Pinebridge Investments L.P. raised its holdings in Inogen by 1.6% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after acquiring an additional 33 shares during the period.

Shares of Inogen Inc (INGN) traded up $0.95 during trading on Thursday, hitting $115.17. 98,254 shares of the stock traded hands, compared to its average volume of 180,969. The stock has a market cap of $2,430.00, a PE ratio of 80.54, a PEG ratio of 4.06 and a beta of 1.13. Inogen Inc has a 1-year low of $62.69 and a 1-year high of $130.05.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The business had revenue of $69.00 million for the quarter, compared to analysts’ expectations of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The company’s revenue was up 26.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.25 EPS. equities research analysts expect that Inogen Inc will post 1.19 earnings per share for the current fiscal year.

INGN has been the topic of several research analyst reports. Zacks Investment Research cut shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub lowered shares of Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Leerink Swann restated an “outperform” rating and set a $120.00 price target (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Finally, Needham & Company LLC upped their price target on shares of Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $102.71.

In other Inogen news, Director Ray Benjamin M. Anderson sold 1,000 shares of Inogen stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $119.06, for a total value of $119,060.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at approximately $119,060. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Raymond Huggenberger sold 14,000 shares of Inogen stock in a transaction on Monday, October 16th. The shares were sold at an average price of $94.07, for a total transaction of $1,316,980.00. Following the completion of the sale, the director now owns 7,808 shares in the company, valued at $734,498.56. The disclosure for this sale can be found here. Insiders have sold a total of 81,500 shares of company stock worth $9,267,695 in the last quarter. Corporate insiders own 5.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “14,672 Shares in Inogen Inc (NASDAQ:INGN) Purchased by GSA Capital Partners LLP” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/01/11/gsa-capital-partners-llp-takes-1-40-million-position-in-inogen-inc-ingn.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply